Biomarin is an English word starting with the letter B. With 10+ example sentences you'll see exactly how it works in context.
Using Biomarin
- In the example corpus, biomarin often appears in combinations such as: biomarin pharmaceutical, in biomarin, of biomarin.
Context around Biomarin
- Average sentence length in these examples: 20.2 words
- Position in the sentence: 4 start, 14 middle, 2 end
- Sentence types: 20 statements, 0 questions, 0 exclamations
Corpus analysis for Biomarin
- In this selection, "biomarin" usually appears in the middle of the sentence. The average example has 20.2 words, and this corpus slice is mostly made up of statements.
- Around the word, downgraded, squibb, pharmaceutical and ptc stand out and add context to how "biomarin" is used.
- Recognizable usage signals include holdings in biomarin pharmaceutical by and shares of biomarin pharmaceutical in. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "biomarin" sits close to words such as actinium, adherent and adipose, which helps place it inside the broader word index.
Example types with biomarin
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
BioMarin Pharmaceutical () last issued its earnings results on Monday, July 31st. (11 words)
Los Angeles Capital Management LLC Invests $666,000 in BioMarin Pharmaceutical Inc. (12 words)
From a strategic and operational standpoint, some investors appear to be underwhelmed with BioMarin. (14 words)
Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of BioMarin Pharmaceutical Inc. () by 1.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). (34 words)
By BioMarin’s count, about 6,500 adults in the U.S. have severe hemophilia A. Of those, the company estimates 2,500 are eligible for Roctavian under the current approval. (31 words)
Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market. (27 words)
Example sentences (20)
As a group, analysts expect that BioMarin Pharmaceutical Inc. will post 1.06 earnings per share for the current year.
Avian Securities downgraded BioMarin Pharmaceutical to a “market perform” rating in a research report on Wednesday, February 22nd.
BioMarin Pharmaceutical () last issued its earnings results on Monday, July 31st.
By BioMarin’s count, about 6,500 adults in the U.S. have severe hemophilia A. Of those, the company estimates 2,500 are eligible for Roctavian under the current approval.
Caprock Group LLC lifted its holdings in BioMarin Pharmaceutical by 6.1% in the 1st quarter.
Finally, MML Investors Services LLC lifted its stake in BioMarin Pharmaceutical by 2.9% during the third quarter.
Finally, Sanford C. Bernstein assumed coverage on shares of BioMarin Pharmaceutical in a research note on Tuesday, March 21st.
Finally, Two Sigma Advisers LP raised its holdings in BioMarin Pharmaceutical by 54.2% in the third quarter.
From a strategic and operational standpoint, some investors appear to be underwhelmed with BioMarin.
Grey Fox Wealth Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $31,000.
Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of BioMarin Pharmaceutical Inc. () by 1.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.
Quadrant Capital Group LLC lifted its position in BioMarin Pharmaceutical by 188.6% during the second quarter.
As a group, equities analysts anticipate that BioMarin Pharmaceutical will post 1.85 EPS for the current fiscal year.
Banque Cantonale Vaudoise’s holdings in BioMarin Pharmaceutical were worth $1,428,000 as of its most recent filing with the Securities and Exchange Commission.
Barclays PLC increased its position in shares of BioMarin Pharmaceutical by 31.6% in the third quarter.
Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd.
Finally, Charles Schwab Investment Management Inc. lifted its holdings in BioMarin Pharmaceutical by 5.7% during the 4th quarter.
ICA Group Wealth Management LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at $31,000.
Los Angeles Capital Management LLC Invests $666,000 in BioMarin Pharmaceutical Inc.
Common combinations with biomarin
These word pairs occur most frequently in English texts:
- biomarin pharmaceutical 29×
- in biomarin 10×
- of biomarin 7×
- that biomarin 4×
- on biomarin 3×